Denali Therapeutics (DNLI) Change in Acquisitions & Divestments (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Change in Acquisitions & Divestments data on file, last reported at $220.0 million in Q1 2026.

• Quarterly Change in Acquisitions & Divestments rose 36.01% year-over-year to $220.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $764.3 million (down 18.32% YoY) and the FY2025 annual result came in at $706.0 million, down 38.98% from the prior year.
• Change in Acquisitions & Divestments fell to $220.0 million in Q1 2026 per DNLI's latest filing, from $275.0 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $601.1 million in Q3 2023 and bottomed at $107.1 million in Q3 2025.
• The 5-year median for Change in Acquisitions & Divestments is $250.5 million (2022), against an average of $303.0 million.
• The widest annual swing landed in 2023, when Change in Acquisitions & Divestments surged 316.46%; it then sank 67.06% in 2024.
• Tracing DNLI's Change in Acquisitions & Divestments over 5 years: stood at $364.0 million in 2022, then soared by 34.34% to $489.0 million in 2023, then slipped by 28.22% to $351.0 million in 2024, then slipped by 21.65% to $275.0 million in 2025, then fell by 20.0% to $220.0 million in 2026.
• Per Business Quant, the three latest DNLI Change in Acquisitions & Divestments figures stand at $220.0 million (Q1 2026), $275.0 million (Q4 2025), and $107.1 million (Q3 2025).

Peer Comparison